Omalizumab beyond asthma
Allergol. immunopatol
; 40(5): 306-315, sep.-oct. 2012. ilus
Artigo
em Inglês
| IBECS
| ID: ibc-106564
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Introduction:
Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient's symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases.Objective:
We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases.Methods:
We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included.Conclusion:
There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases(AU)RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Asma
/
Urticária
/
Imunoglobulina E
/
Receptores de IgE
/
Hipersensibilidade Alimentar
/
Anticorpos Monoclonais
Tipo de estudo:
Estudo diagnóstico
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Group of Clinical and Experimental Allergology/Colombia